Anti-CD37 targeted immunotherapy of B-Cell malignancies |
| |
| Authors: | Zahra Payandeh Effat Noori Bahman Khalesi Maysam Mard-Soltani Jalal Abdolalizadeh Saeed Khalili |
| |
| Institution: | 1.Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine,Zanjan University of Medical Sciences,Zanjan,Iran;2.Cellular and Molecular Biology Research Center,Shahid Beheshti University of Medical Sciences,Tehran,Iran;3.Department of Research and Production of Poultry Viral Vaccine, Razi Vaccine and Serum Research Institute,Agricultural Research Education and Extension Organization (AREEO),Karaj,Iran;4.Department of Clinical Biochemistry, Faculty of Medical Sciences,Dezful University of Medical Sciences,Dezful,Iran;5.Drug Applied Research Center, Faculty of Medicine,Tabriz University of Medical Sciences,Tabriz,Iran;6.Department of Biology Sciences,Shahid Rajaee Teacher Training University,Tehran,Iran |
| |
| Abstract: | CD37 is a member of tetra-spanning superfamily (characterized by their four transmembrane domains). It is one of the specific proteins for normal and malignant mature B cells. Anti CD37 monoclonal antibodies are reported to improve the overall survival in CLL. These therapeutics will increase the efficacy and reduce the toxicity in patients with both newly diagnosed and relapsed and refractory disease. Recent clinical trials have shown promising outcomes for these agents, administered both as monotherapy and in combination with standard chemotherapeutics. Long-term follow-up of combination regimens has even raised the question of whether the patients with CLL could be treated with intensive chemo-immunotherapy. In the present study, CD37 is introduced as an appealing target to treat B cell malignancies. The anti-CD37 antibodies as one of the most successful therapeutics against CD37 are introduced and the clinical outcomes of their exploitation are explained. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
